Holmgaard, Rikke B.
Eli Lilly (United States)
3 papers on CoChatORCID 0000-0002-6579-461X
Most cited papers
- Verified
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine
Virus-based gene therapy researchCancer Immunotherapy and Biomarkers
Cited by 711
- Verified
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., et al. (2018) · Journal for ImmunoTherapy of Cancer
TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers
Cited by 356
- Verified
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first‐in‐class transforming growth factor‐β receptor type I inhibitor
Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., Clawson, D. K., Britt, K. S., Anderson, B. D., Beight, D. W., et al. (2018) · Oncotarget
TGF-β signaling in diseasesMechanisms of cancer metastasis
Cited by 187
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free